Clinical trial NCT00822601: Study of Repetitive Transcranial Magnetic Stimulation Efficacy on Obsessive Compulsive Disorder (OCD)
Official title: A Controlled Study of rTMS Over Supplementary Motor Area (SMA) in Obsessive Compulsive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Obsessive-Compulsive Disorder
Keywords: Repetitive Transcranial Magnetic Stimulation
Supplementary Motor Area
Obsessive-Compulsive Disorder
Sham rTMS
Placebo-controlled
Randomized
Double-blind
fMRI
DSM-IV Obsessive-Compulsive Disorder
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2009-01-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our study's purpose is to show the efficacy of the transcranial magnetic stimulation (a non invasive method of cerebral modulation) in patients suffering from chronic obsessive compulsive disorder (OCD). This new method will be applied in 20 patients during 4 weeks (5 sessions each week), and its effects on OCD symptoms will be compared to those of a "sham" (=placebo) stimulation applied with the same process in 20 other patients, randomly assigned to the comparison group. The maintenance of the therapeutic effects will be explored during 8 weeks following the end of the treatment. In addition to classical scales used to measure the treatment effects, all patients will be examined using a functional magnetic resonance imaging (fMRI) before and after treatment to explore the cerebral effects of rTMS

Detailed description: Repetitive Transcranial Magnetic Stimulation (rTMS) has been shown to be an effective therapeutic tool for the treatment of several neuropsychiatric disorders including major depression and hallucinations in schizophrenia but, to date, studies exploring the effects of rTMS in Obsessive Compulsive Disorder (OCD) have produce negative or conflicting results, especially those applying the stimulation to the prefrontal cortex as for the treatment of depression. However, a promising result has been obtained in a study in which the rTMS was applied to the Supplementary Motor Area (SMA), but in a small size and heterogeneous sample. The SMA has connections with areas of the brain, especially motor areas and subcortical-limbic circuitry, implicated in OCD.

In our study, 40 adult outpatients with OCD, who have been insufficiently responsive to at least two recognized drug treatments, will be randomly assigned to one of two treatment groups (active low frequency (1 Hz, 100% of the motor threshold) rTMS or sham-placebo) applied to the SMA daily for up to four weeks. An individual MRI-guided neuronavigation will be used to precisely define the target stimulation site in each patient. Rating scales for symptom change will be obtained at baseline, during the rTMS course, at the end of 4 weeks of treatment, and after a 2-month follow-up period. The main outcome measure will be the Yale-Brown Obsessive Compulsive scale, and secondary outcome measure will include the CGI scales, the LPO scale, the MOCI, and the SDS. Brain activity changes in fMRI before and after active/sham treatment will be compared between groups, with rest measures and provocation tasks.

Eligibility criteria: Inclusion Criteria:

* signed patient informed consent;
* primary obsessive compulsive disorder;
* current YBOCS score at least 15 with or without drug (or obsessive/compulsive subscores of at least 10);
* males/females 18-65yrs;
* treated with at least two adequate dose of SRI at least 8 weeks at some stage of illness;
* currently using adequate, stable dose of SSRI at least 8 weeks but not responding.

Exclusion Criteria:

* schizophrenia, other psychotic disorders, bipolar I, current major depressive disorder (MADRS\>20), substance/alcohol dependence within last 6 months;
* severe axis II;
* significant suicide risk;
* metallic implant in cranium;
* severe/unstable medical conditions;
* ECT in the last month;
* pregnancy or breastfeeding ;
* history epilepsy; neurological disorder leading to increased intracranial pressure; severe cardiac disorder/intracardiac lines, pacemakers; Gilles de la Tourette syndrome;
* current structured psychotherapy;
* current drug treatment of bipolar disorder.

Primary outcomes:
measure: Yale-Brown Obsessive Compulsive Scale (YBOCS)
timeFrame: week 1, 2, 3, 4, 5, 7, 9, 11, 13
Secondary outcomes:
measure: Clinical Global Impression - Severity (CGI-S)
timeFrame: week 1, 2, 3, 4, 5, 7, 9, 11, 13
measure: - Clinical Global Impression - Improvement (CGI-I)
timeFrame: week 1, 2, 3, 4, 5, 7, 9, 11, 13
measure: Global Assessment of Functioning (GAF)
timeFrame: week 5, 13
measure: - Montgomery Asberg Depression Rating Scale (MADRS)
timeFrame: week 5, 13
measure: Brief Anxiety Scale (BAS
timeFrame: week 5, 13
measure: Sheehan Disability Scale (SDS)
timeFrame: , week 5, 13
measure: Hospital Anxiety and Depression (HAD) scale
timeFrame: week 1, 2, 3, 4, 5, 7, 9, 11, 13
measure: Maudsley Obsessional Inventory (MOCI)
timeFrame: week 5, 13
measure: LPO scale
timeFrame: week 5, 13
Other outcomes:
Locations:
city: Paris
country: France
facility: Pitie Salpetriere Hospital
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Antoine Pelissolo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: